Ovid Therapeutics Files 8-K on Agreements and Equity Sales
Ticker: OVID · Form: 8-K · Filed: 2025-10-03T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: OVID
TL;DR
Ovid Therapeutics filed an 8-K detailing new agreements, equity sales, and corporate changes as of Oct 2, 2025.
AI Summary
Ovid Therapeutics Inc. filed an 8-K on October 3, 2025, reporting on several events as of October 2, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, and amendments to its articles of incorporation or bylaws. The filing also notes other events and financial statements/exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Ovid Therapeutics, including potential new agreements and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.
Key Numbers
- 001-38085 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5270895 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- October 2, 2025 (date) — Earliest event reported
- October 3, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 441 Ninth Avenue, 14th Floor New York, New York 10001 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Ovid Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into as of October 2, 2025.
What type of equity securities were sold in the unregistered sale?
The filing indicates unregistered sales of equity securities occurred, but does not specify the type or amount of securities sold.
What specific amendments were made to Ovid Therapeutics' articles of incorporation or bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws' as an item reported, but does not provide the specific details of these amendments.
What are the 'Other Events' reported in this 8-K filing?
The filing mentions 'Other Events' as a reported item but does not elaborate on what those specific events are.
When is Ovid Therapeutics' fiscal year end?
Ovid Therapeutics' fiscal year ends on December 31st.
Filing Stats: 2,635 words · 11 min read · ~9 pages · Grade level 13.8 · Accepted 2025-10-03 17:09:37
Key Financial Figures
- $0.001 — hich registered Common Stock par value $0.001 per share OVID The Nasdaq Stock Mar
- $1,400.00 — ies will be sold at a purchase price of $1,400.00 per Security to the Investors, which in
- $1.40 — nts will each have an exercise price of $1.40 per share. The PIPE financing is expe
- $175.1 million — ed to result in gross proceeds of up to $175.1 million to the Company, including initial gross
- $80.8 m — initial gross proceeds of approximately $80.8 million, in each case before placement ag
- $1,400 — d an amount equal to the greater of (i) $1,400 per share of Series B Preferred Stock,
Filing Documents
- d45212d8k.htm (8-K) — 47KB
- d45212dex31.htm (EX-3.1) — 80KB
- d45212dex41.htm (EX-4.1) — 147KB
- d45212dex42.htm (EX-4.2) — 151KB
- d45212dex101.htm (EX-10.1) — 219KB
- d45212dex102.htm (EX-10.2) — 121KB
- d45212dex991.htm (EX-99.1) — 34KB
- g45212g1003123142339.jpg (GRAPHIC) — 7KB
- 0001193125-25-230409.txt ( ) — 1139KB
- ovid-20251002.xsd (EX-101.SCH) — 3KB
- ovid-20251002_lab.xml (EX-101.LAB) — 18KB
- ovid-20251002_pre.xml (EX-101.PRE) — 11KB
- d45212d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. 4.1 Form of Series A Warrant. 4.2 Form of Series B Warrant. 4.3 Form of Pre-Funded Warrant (included as Exhibit A to the Form of Series A Warrant filed as Exhibit 4.1). 10.1 Securities Purchase Agreement, dated as of October 2, 2025, by and among Ovid Therapeutics Inc. and the Investors named therein. 10.2 Form of Registration Rights Agreement. 99.1 Press Release, dated October 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized Date: October 3, 2025 OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer